in performance: james mcmurtry and justin townes earle

How ironic that James McMurtry, in deflecting conversation about the assumed literary inspiration of screenwriter/novelist dad Larry McMurtry at last night’s Kentucky Theatre taping of the WoodSongs Old-Time Radio Hour, would reference the father of the program’s other guest, Justin Townes Earle.

So came this quote from Americana renegade Steve Earle: “Songs are just literature you can digest while driving.”

True to that notion, and despite a few, very atypical WoodSongs broadcast glitches (the fortunes of war in any live radio setting), the tunes of McMurtry and Earle served as expert vehicles for tales set in the very wild, bluesy yonder.

McMurtry stuck entirely to the darker rural material from his new Just Us Kids album. He turned Dylan-esque phrasing into swampy retribution on Hurricane Party before courting the stark Texan storytelling prowess of Townes Van Zandt while singing for all the world like Lou Reed during the downward crackhead spiral of Fire Line Road.

Crisp, wiry support by McMurtry’s Heartless Bastards band (funny… no one mentioned that moniker on the air) came to a head on Just Us Kids‘ title tune, which, in keeping with the show’s unintended family theme, the singer dedicated to his teenage son. The more worldly dismay of You’d a Thought (Leonard Cohen Must Die), the closing song on Just Us Kids, was served as an encore.

The younger Earle (yes, his middle name is a tribute to Van Zandt) sounded less like his father and more like Hank Williams. When matched with the mandolin, banjo, and very serviceable vocal harmonies of co-hort Cory Younts, Earle’s unadorned country musings fueled the hootenanny Hard Livin’ and the swing-savvy turns in an update of Fiddlin’ Arthur Smith’s Chitlin’ Cookin’ Time in Cheatham County.

Topping it all was The Ghost of Virginia, an encore tune pulled from Earle’s Yuma EP disc that reveled in the cherished country imagery of a train running like a lost soul in the moonlight with cold steel tracks as its only companion.

The imagery may have been cold, but the performance couldn’t have been cooler.

MD Anderson Cancer Center to Investigate Potential Anti-tumor Effects of CG100649, CrystalGenomics’ Novel NSAID Candidate.

Biotech Week October 20, 2010 CrystalGenomics, Inc. (www.cgxinc.com), a biopharmaceutical company with drug discovery and development capabilities, has just announced its plan to jointly conduct an investigational preclinical research project with The University of Texas MD Anderson Cancer Center. The purpose of this research is to explore the potential anti-tumor effects of CG100649, CrystalGenomics’ clinical stage novel NSAID candidate, which is being developed as an osteoarthritis drug (see also Osteoarthritis).

CrystalGenomics’ role in these efforts will be to provide CG100649 for studies in mouse models to determine if the drug prevents adenoma formation. CG100649 is believed to have a cancer prevention mechanism and a superior safety profile compared to existing cyclooxygenase-2 (COX-2) inhibitors on the market today and this research is designed to validate this in the area of colorectal cancer. Depending on the results of the research, CrystalGenomics may expand CG100649’s indication to also include the prevention of colorectal cancer. site md anderson cancer center

The principal investigator for the research will be Dr. Raymond DuBois, an internationally renowned investigator and researcher in the field of cancer, especially in the link between colorectal cancer, arthritis drugs and the COX-2 enzyme. Dr. DuBois has served as president of the American Association for Cancer Research and currently is the provost and executive vice president of MD Anderson.

Dr. DuBois’ laboratory at MD Anderson seeks to advance the understanding, diagnosis, treatment and prevention of colorectal cancer. DuBois and colleagues discovered that bioactive lipids and inflammation play important roles in the process of colorectal cancer prevention and were among the first to recognize that COX enzymes play a pivotal role in the formation of adenomatous polyps and colorectal cancer. These discoveries led to successful clinical translational studies applying the use of non-steroidal anti-inflammatory drugs (NSAIDs), which included COX-2 inhibitors, in the treatment of high-risk colorectal cancer patients. here md anderson cancer center

President & CEO of CrystalGenomics, Dr. Joong Myung Cho said, “We are very excited to work with a world renowned cancer center and to have the research led by a premier investigator. There is a tremendous potential for our CG100649 program as there are great unmet medical needs in the areas of both osteoarthritis and colorectal cancer.”



Comments are closed.


Terms of Service | Privacy Policy | About Our Ads | Copyright